A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

October 31, 2026

Conditions
Mid Face Volume Deficit
Interventions
DEVICE

HArmonyCa Lidocaine Injectable Gel

Subdermal or Deep Dermal or Supraperiosteal Injection

DEVICE

Restylane® Perlane® Lidocaine

Subcutaneous to Supraperiosteal Implantation Injection

Trial Locations (9)

100005

Beijing Hospital /ID# 272476, Beijing

100032

Peking Union Medical College Hospital (West) - Xidan Campus /ID# 272480, Beijing

200040

Huashan Hospital Of Fudan University /ID# 272632, Shanghai

200065

Shanghai Tongji Hospital /ID# 272509, Shanghai

210008

Nanjing Drum Tower Hospital /ID# 272468, Nanjing

210009

Zhongda Hospital Southeast University /ID# 272471, Nanjing

214023

Wuxi People'S Hospital /ID# 275928, Wuxi

310006

The First People's Hospital of Hangzhou /ID# 272475, Hangzhou

430022

Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 272631, Wuhan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY